Nephros Covid-19 Operational Update

Nephros to Report Third Quarter 2018 Financial Results on November 8th, 2018

SOUTH ORANGE, NJ, November 1, 2018 – Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, today announced that it will issue its third quarter 2018 financial results on Thursday, November 8, 2018. The company will also host a conference call at 4:30 PM ET that afternoon, during which management will discuss the company’s financial results and provide a general business overview of both Nephros and its subsidiary, Specialty Renal Products (SRP), a private company focused on the development of products for patients with renal disease, including a hemodiafiltration (HDF) system for the treatment of patients with End Stage Renal Disease (ESRD).

Participants may dial into the following number to access the call: 1-866-652-5200 or international callers using 1-412-317-6060. Please ask to be joined into the Nephros conference call. A replay of the call can be accessed until November 15, 2018 at 1-877-344-7529 or 1-412-317-0088 for international callers, and entering Replay Access Code: 10126116. An audio archive of the call will be available shortly after call on the Nephros investor relations page at

About Nephros, Inc.

Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters, known as ultrafilters. Nephros ultrafilters are primarily used in hospitals and medical clinics for added protection in retaining bacteria (e.g., Legionella, Pseudomonas), viruses, and endotoxins from water. They provide barriers that assist in improving infection control in showers, sinks, and ice machines. Additionally, Nephros ultrafilters are used by dialysis centers for assisting in the added removal of biological contaminants from the water and bicarbonate concentrate supplied to hemodialysis machines and the patients.

For more information about Nephros, please visit the company’s website at

Investor Relations Contact:
Andy Astor
CFO, Nephros
(201) 345-0824